This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability

This study has been withdrawn prior to enrollment.
Information provided by:
Duke University Identifier:
First received: December 5, 2009
Last updated: January 15, 2013
Last verified: January 2013

The purpose of this research is to address the comparative effectiveness and harm of the therapeutics frequently given to pregnant women and their young infants including antibiotics, tocolytic agents, non-steroidal anti-inflammatory drugs, H2 blockers, and steroids.

Our overall hypothesis is that the use of an existing electronic medical record with additional resources for precise data collection and 18 month follow up will successfully address current knowledge gaps in therapeutic effectiveness and relative therapeutic harm.

We will use an existing electronic medical record into which detailed healthcare information is entered for over 100,000 newborns each year. These infants will comprise the "Source Cohort". Nested within that database, we will prospectively enroll 10% of the population (10,000 newborns) as the Follow-Up Cohort.

The current electronic medical record for the Source Cohort does not capture therapeutic dosing with sufficient precision to conduct comparative effectiveness research sufficient to change medical practice. The proposed research will: 1) ensure accurate data collection through electronic monitoring and real-time quality assurance evaluation in the Source Cohort; and 2) conduct 18 months post-hospital follow-up for neurologic outcomes and disability for the Follow-Up Cohort. We will complete assessments of neurologic outcomes and disability using an interactive web-based system, mail, telephone follow up, and in-person examination.

Gastroesophageal Reflux Presumed Sepsis Patent Ductus Arteriosus Chronic Lung Disease Neurodevelopmental Impairment

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability

Resource links provided by NLM:

Further study details as provided by Duke University:

Enrollment: 0
Study Start Date: August 2010
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Extremely Premature Infants
< 30 weeks gestation (N=5000)
Premature Infants
30-36 weeks gestation (N=2000)
Hospitalized Term Infants
>=37 weeks gestation (N=2000)
Healthy Term Infants
>=37 weeks gestation (N=1000)


Ages Eligible for Study:   up to 5 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
We will enroll 10,000 infants at 40 centers. Infants will be enrolled into one of four strata: extremely premature (<30 weeks, n=5,000), premature (30-36 weeks inclusive n=2,000), hospitalized term (≥37 weeks gestation, n=2,000), and healthy term (≥37 weeks gestation, n=1,000).

Inclusion Criteria:

  • Admitted to the a Pediatrix Medical Group NICU
  • <=5 days of life
  • likely to follow-up at 18 months adjusted age

Exclusion Criteria:

  • failure to consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01028183

United States, North Carolina
Duke Clinical Research Institute
Durham, North Carolina, United States, 27715
Sponsors and Collaborators
Duke University
Principal Investigator: Daniel K Benjamin, MD PhD MPH Duke Clinical Research Institute
  More Information

Responsible Party: Daniel K Benjamin Jr MD PhD MPH, Associate Professor of Pediatrics, Duke Clinical Research Institute Identifier: NCT01028183     History of Changes
Other Study ID Numbers: IRB pending
Study First Received: December 5, 2009
Last Updated: January 15, 2013

Keywords provided by Duke University:

Additional relevant MeSH terms:
Lung Diseases
Gastroesophageal Reflux
Ductus Arteriosus, Patent
Respiratory Tract Diseases
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities
Coal Tar
Keratolytic Agents
Dermatologic Agents processed this record on September 19, 2017